Page last updated: 2024-12-06

fluparoxan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fluparoxan is a selective, high-affinity antagonist of the 5-HT1A receptor. It is a non-selective antagonist, meaning it blocks both pre- and post-synaptic 5-HT1A receptors. Fluparoxan is a potent anxiolytic and antidepressant in animal models. Its synthesis involves several steps, including the formation of a piperidine ring and the introduction of a fluoro group. Its effects include reducing anxiety, increasing serotonin levels in the brain, and possibly having anti-depressant effects. Fluparoxan is studied because it has shown promise in treating anxiety and depression and may serve as a lead compound for the development of new drugs for these disorders.'

fluparoxan: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72036
CHEMBL ID1765294
SCHEMBL ID112164
MeSH IDM0179243

Synonyms (36)

Synonym
gr-50,360
gtpl41
(3as,9as)-8-fluoro-2,3,3a,9a-tetrahydro-1h-[1,4]benzodioxino[2,3-c]pyrrole
fluparoxan
(3as,9as)-5-fluoro-2,3,3a,9a-tetrahydro-1h-[1,4]benzodioxino[2,3-c]pyrrole
(3as,9as)-fluparoxan
fluparoxan, (-)-
(-)-fluparoxan
CHEMBL1765294
gr 50360
gr 50360a
105182-45-4
AKOS006272841
wga8e072gx ,
1h-(1,4)benzodioxino(2,3-c)pyrrole, 5-fluoro-2,3,3a,9a-tetrahydro-, (3as,9as)-
fluparoxanum [latin]
fluparoxanum
unii-wga8e072gx
fluparoxan [inn:ban]
1h-(1,4)benzodioxino(2,3-c)pyrrole, 5-fluoro-2,3,3a,9a-tetrahydro-, (3as-trans)-
fluparoxan [who-dd]
(3as,9as)-5-fluoro-2,3,3a,9a-tetrahydro-1h-(1,4)benzodioxino(2,3-c)pyrrole
fluparoxan [inn]
SCHEMBL112164
DTXSID80146995
Q5462882
rel-(3ar,9ar)-5-fluoro-2,3,3a,9a-tetrahydro-1h-(1,4)benzodioxino(2,3-c)pyrrole
(+/-)-fluparoxan
(3ar,9ar)-rel-fluparoxan
1n6wyi0ka0 ,
unii-1n6wyi0ka0
1h-(1,4)benzodioxino(2,3-c)pyrrole, 5-fluoro-2,3,3a,9a-tetrahydro-, trans-
101389-86-0
1h-(1,4)benzodioxino(2,3-c)pyrrole, 5-fluoro-2,3,3a,9a-tetrahydro-, trans-(+/-)-
fluparoxan, (+/-)-
1h-(1,4)benzodioxino(2,3-c)pyrrole, 5-fluoro-2,3,3a,9a-tetrahydro-, (3ar,9ar)-rel-

Research Excerpts

Overview

Fluparoxan is an alpha 2-adrenoceptor antagonist. It was considered a potential substrate and inducer of cytochrome P4501A (CYP1A) enzymes.

ExcerptReferenceRelevance
"1. Fluparoxan is an alpha 2-adrenoceptor antagonist that has a relatively planar, tricyclic structure and was considered a potential substrate and inducer of cytochrome P4501A (CYP1A) enzymes. "( Cytochrome P4501A (CYP1A) induction in rat and man by the benzodioxino derivative, fluparoxan.
Ayrton, J; Beresford, AP; Ellis, WJ; Johnson, MA; Lewis, DF, 1997
)
1.14

Treatment

ExcerptReferenceRelevance
"Fluparoxan treatment prevented age-related spatial working memory deficits in the spontaneous alternation task but not spatial reference memory deficits in the Morris water maze."( Chronic treatment with the α2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP×PS1 transgenic mice without altering β-amyloid plaque load or astrocytosis.
Kendall, DA; Marsden, CA; Pardon, MC; Scullion, GA; Sunter, D,
)
1.1

Dosage Studied

ExcerptRelevanceReference
" Routine enantiomeric analyses were successfully carried out on samples taken from animals dosed orally with the racemic drugs, providing important data on the possible levels of exposure to individual enantiomers during toxicity testing."( Advantages of achiral h.p.l.c. as a preparative step for chiral analysis in biological samples and its use in toxicokinetic studies.
Beresford, AP; Caswell, K; Chambers, R; Kirk, IP, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)2000Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic tr
AID624210Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A2000Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic tr
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (76.92)18.2507
2000's1 (7.69)29.6817
2010's2 (15.38)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.12 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (14.29%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (78.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]